KPF
CSCI

K2 Principal Fund’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

K2 Principal Fund’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-602
Closed -$60K – 415
2017
Q2 		$60K Buy
+602
New +$95.4K ﹤0.01% 335

Other funds holding CSCI

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
NCCM
Nine Chapters Capital Management Short Hills, New Jersey $45.4M AUM 14.43% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

K2 Principal Fund's CSCI Position: Q3 2017 in Review

K2 Principal Fund sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2017, closing a stake of 602 shares — an estimated $60K sold.

K2 Principal Fund first reported a position in CSCI in Q2 2017 and held it in 1 quarter. The position peaked at $60K in Q2 2017. 18 funds tracked by Wall St. Rank hold CSCI as of Q3 2017.

  • K2 Principal Fund reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • K2 Principal Fund sold 602 COSCIENS Biopharma Inc. Common Stock shares in Q3 2017, an estimated $60K.
  • K2 Principal Fund first reported a position in COSCIENS Biopharma Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • K2 Principal Fund's COSCIENS Biopharma Inc. Common Stock position peaked at $60K in Q2 2017.
  • 18 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2017.

Based on K2 Principal Fund's 13F filing for Q3 2017, filed 9 Nov 2017.